Use of the mTOR inhibitor everolimus in the treatment of postmenopausal HR+/HER2– metastatic breast cancer can be hampered by the development of stomatitis/mouth ulcers, which can lead to dose reductions and treatment discontinuation.

A new approach of slowly escalating the dose of everolimus reduces the risk of this adverse event, says a group of...